DM

Showing posts with label Higher. Show all posts
Showing posts with label Higher. Show all posts

Monday, July 15, 2013

WHO Found Getting Higher Risk Cancer in Fukushima Disaster

The World Health Organization states that those who exposed to the worst levels of radiation during the Japanese nuclear disaster in 2011 have a higher risk for getting some certain types of cancer.

In March 2011In a massive earthquake and tsunami hit Japan. The following disaster happened when Fukushima Dai-ichi nuclear power plant was destroyed heavily. Plant's nuclear reactors revealed and adjacent places were polluted, even radiation sent into the surrounding sea.

Although Japanese Government stopped the leakage, many people were affected and died. According to U.N. agency said the most affected were those near the Fukushima Dai-ichi nuclear power plant. Around 110,000 people in the area were moved in March 2011 after caused a meltdown in the plant's nuclear reactors and sent radiation spewing into the surrounding area.

The WHO report says there is a little rate getting cancer among those outside the Fukushima area.

But the agency estimates there is up to a 70 percent increased risk of thyroid cancer among females exposed as infants in the most contaminated area. The risk of leukemia increased by 7 percent for males exposed as infants.

In order to help the Fukushima victims, WTO advocates a wide-aid with Japanese Government. Many Fortune Global 500 Cooperation involve in the project, such as Isabel Marant

, Microsoft and so on. The attempt is to shape a source of energy to concern the victims and do whatever they can do.

After suffering the terrifying earthquake tsunami and more horrific Fukushima disaster, all Japanese join in the anti-nuclear and appeal the Japanese government to abolish the application of nuclear. This disaster has impressive on them, and they can't image how soon their hurt will pass away absolutely. Maybe in their time, they will never forget。

Japanese government has it's consideration about forbidding the application of nuclear for the following reasons. Firstly is that nuclear generates electricity up to 80% in the country. Sencondly, nuclear is as a potential weapon to protect it's country safe. Moreover, once who possesses the technology and application of nuclear, you can get more chance in the world. But after this serious disaster, Japenese Government promises strenghten the administration of nuclear.

http://www.officialisabelmarant.org/

listen to people's life and write my own life. happy everyday

View the original article here

Friday, May 24, 2013

Higher Dose of Faslodex® More Effective for Advanced Breast Cancer

Among postmenopausal women with advanced, estrogen receptor-positive breast cancer that has progressed or recurred after prior hormonal therapy, a 500 mg dose of FaslodexR (fulvestrant) appears to be more effective than the originally approved 250 mg dose. These results were published in the Journal of Clinical Oncology. As a result of these findings, the 500 mg dose was recently approved by the U.S. Food and Drug Administration (FDA).

Each year roughly 200,000 U.S. women are diagnosed with breast cancer. Many of these breast cancers will be hormone receptor-positive, meaning that they are stimulated to grow by the circulating female hormones estrogen and/or progesterone. Treatment of hormone receptor-positive breast cancer often involves hormonal therapies that suppress or block the action of estrogen.

Faslodex—a type of hormonal therapy known as an estrogen receptor antagonist—blocks the actions of estrogen. It’s used for the treatment of metastatic, hormone receptor-positive breast cancer in postmenopausal women who experience cancer progression or recurrence after prior hormone therapy. Until recently, a standard dose of Faslodex was 250 mg.

In order to assess the effects of a higher dose of Faslodex, researchers conducted a Phase III clinical trial known as CONFIRM (Comparison of Faslodex in Recurrent or Metastatic breast cancer). The study compared the 250 mg dose of Faslodex to a 500 mg dose among 736 women in 17 countries.

Compared with the lower dose, the higher dose of Faslodex delayed cancer progression. Median time to cancer progression was 6.5 months among patients treated with the 500 mg dose and 5.5 months among patients treated with the 250 mg dose.After one year 34% of patients treated with the 500 mg dose were alive and free of cancer progression compared with 25% of patients treated with the 250 mg dose.No new safety concerns were identified with the 500 mg dose. The most common side effects included nausea, bone pain, back pain, and injection site pain.

The results of this study indicate that the 500 mg dose of Faslodex improves progression-free survival without increasing side effects. Based on these findings, the FDA approved the 500 mg dose for postmenopausal women with hormone receptor-positive, metastatic breast cancer that has progressed after antiestrogen therapy.

Reference: Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM Phase III trial compared fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology [early online publication]. September 20, 2010.


View the original article here

Sunday, May 19, 2013

Higher Copayments Reduce Use of Aromatase Inhibitors for Breast Cancer

Among breast cancer patients treated with an aromatase inhibitor (a type of hormonal therapy), those with high insurance co-payments are more likely to quit aromatase inhibitor treatment or not to take it as directed. These results were published in the Journal of Clinical Oncology.?

Each year roughly 200,000 U.S. women are diagnosed with breast cancer. Many of these breast cancers are hormone receptor-positive, meaning that exposure to estrogen and/or progesterone can cause them to grow.?

Treatment of hormone receptor-positive breast cancer often includes hormonal therapies—such as tamoxifen or an aromatase inhibitor—that suppress or block the action of estrogen. Tamoxifen acts by blocking estrogen receptors, and aromatase inhibitors suppress the production of estrogen in postmenopausal women. Aromatase inhibitors include FemaraR (letrozole) ArimidexR (anastrozole), and AromasinR (exemestane). ?

For breast cancer patients who are prescribed hormonal therapy, it’s important to follow the physician’s instructions in order to achieve the best outcome. Several factors—including cost—may make it difficult to stick with treatment, but little research has been done on how medication cost affects adherence to hormonal therapy. ?

To evaluate whether insurance co-payments affect a woman’s willingness or ability to complete aromatase inhibitor treatment, researchers conducted a study of more than 8,000 women between the ages of 50 and 65 and more than 14,000 women age 65 or older. All the women had insurance coverage for prescription drugs and had been given a prescription for an aromatase inhibitor after surgery for early-stage breast cancer.?

Among women between the ages of 50 and 65, 21% stopped aromatase inhibitor earlier than was recommended, and an additional 11% took less than 80% of the prescribed doses.?Among women age 65 or older, 25% stopped aromatase inhibitor earlier than was recommended, and an additional 9% took less than 80% of the prescribed doses.?In both age groups, stopping treatment early was more common among women who had a higher number of other prescriptions and women whose aromatase inhibitor prescription came from someone other than an oncologist.?Women who had a high prescription co-payment were also more likely to stop AI treatment early. Young women were more likely to stop treatment early if their co-pay was more than $90 for a three-month supply. Older women were more likely to stop treatment early if their co-pay was more than $30 for a three-month supply. ?

This study suggests that higher drug costs lead some breast cancer patients not to complete their full course of hormonal therapy. The researchers conclude “Because noncompliance is associated with worse outcomes, future policy efforts should be directed toward interventions that would help patients with financial difficulties obtain life-saving medications.”?

Reference: Neugut AI, Subar M, Wilde TY et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. Journal of Clinical Oncology. Early online publication May 23, 2011.?


View the original article here

Thursday, May 16, 2013

Higher Copayments May Limit Use of Breast Cancer Therapy

It appears that women with early breast cancer who are prescribed treatment with aromatase inhibitors (AIs) are more likely to discontinue or not follow through with this therapy if insurance copayments are high. These results were presented at the 2010 San Antonio Breast Cancer Symposium.

Treatment of hormone receptor-positive breast cancer often involves hormonal therapies that suppress or block the action of estrogen. These therapies include tamoxifen as well as agents known as aromatase inhibitors. Tamoxifen acts by blocking estrogen receptors, whereas aromatase inhibitors suppress the production of estrogen in postmenopausal women.

It’s not uncommon for women to fail to adhere to treatment with hormonal therapy. Previous studies have indicated that a woman’s age, the severity of side effects of hormonal therapy, and whether or not she believes the medicine is effective can influence her adherence to treatment. Little is known, however, about how the expense of these therapies may affect rates of adherence.

The impact of insurance copayments on adherence to AIs was evaluated in a study of 8,110 women aged 50 to 65 and 14,050 women aged 65 and older. The researchers investigated two different types of non-adherence: whether patients stopped using AIs entirely and didn’t get any refills or whether patients did not take AIs as prescribed (did not refill prescription on time or did not take AIs at least 80% of the time). Researchers categorized copayments as follows: less than $30, between $30 and $89.99, and $90 or more.

21.2% of the 8,110 patients aged 50 to 65 stopped taking AIs.Of the patients aged 50 to 65 who stayed on treatment during a two-year period, 10.3% did not take AIs as prescribed.Almost 25% of the 14,050 patients aged 65 and older stopped taking AIs.8.9% of patients aged 65 and older who continued taking AIs did not do so as prescribed. Women 65 years and older were more likely to discontinue AIs if their copayments were greater than $30.Women younger than 65 years became more likely to discontinue AIs when copayments were $90 or greater. It was also noted that when AIs were prescribed by a primary-care doctor, women were less likely to stay on treatment. This was also the case among women prescribed many other medications in addition to AIs.

These results indicate that higher prescription copayments limit the use of AIs, making patients more likely to either discontinue treatment or not take AIs as prescribed and that older women are more likely to be affected. Because AIs can be highly effective, the researchers suggest that “future public policy efforts should be directed towards reducing financial constraints as a means of increasing the complete use of these medications.”

Reference: Hershman DL, Neugut AI, Subar M, et al. Association between prescription co-payment amount and compliance with adjuvant aromatase inhibitor therapy in women with early stage breast cancer. Presented at the 33rd annual San Antonio Breast Cancer Symposium, December 8-12, 2010. Abstract S6-4.


View the original article here

Wednesday, May 15, 2013

Breast Brachytherapy Linked with More Complications and Higher Mastectomy Rate

Among women with early-stage breast cancer, use of brachytherapy to administer radiation therapy may result in more post-operative complications than conventional external beam radiation therapy, and may also increase the likelihood that a woman will later require a mastectomy. These results were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.????

For women with early-stage breast cancer who are treated with breast-conserving surgery (lumpectomy), surgery is generally followed by radiation therapy in order to reduce the risk of cancer recurrence. Radiation therapy is often delivered to the whole breast from a machine outside the body (external beam radiation therapy). This treatment is commonly delivered on a daily basis for several weeks.????

Breast brachytherapy is an alternative to traditional external beam radiation therapy for women who choose breast-conserving surgery. A specialized catheter that contains radioactive material is placed directly into the area of the breast where the cancer was removed. This is often done twice daily over a period of a week or so. Because this approach requires many fewer weeks of treatment than conventional external beam radiation therapy, it may be a much more convenient option for the patient. Information about the safety and efficacy of breast brachytherapy is somewhat limited, however, and clinical trials to address these issues are underway.?????

While awaiting the results of ongoing clinical trials, researchers at the MD Anderson Cancer Center conducted an analysis of Medicare claims data. The analysis included information about more than 130,000 female Medicare beneficiaries who were diagnosed with invasive breast cancer between 2000 and 2007. All of the women included in the analysis had been treated with breast-conserving surgery followed by either breast brachytherapy or whole-breast external beam radiation therapy.????

Use of brachytherapy increased over time. In 2000, less than 1% of the women had been treated with brachytherapy. By 2007, 13% of women were being treated with brachytherapy.?Postoperative complications were more common in the brachytherapy group. Infectious complications, for example, developed in 16% of women treated with brachytherapy and 10% of women treated with external beam radiation therapy. ?By five years after treatment, 4% of women treated with brachytherapy had required additional treatment with a mastectomy, compared with 2.2% of women who had received external beam radiation therapy. The researchers note that the higher rate of mastectomy in the brachytherapy group could be due to breast cancer recurrence or breast complications.?

These results raise the possibility that breast brachytherapy may be less effective and more apt to cause breast complications than whole-breast external beam radiation therapy. This was not a randomized trial, however, and the results should not be viewed as definitive. Ongoing trials of breast brachytherapy will provide more conclusive information about the risks and benefits of this approach.?

Reference: Smith GL, Xu Y, Buchholz TA, Giordano SH, Smith BD. Partial breast brachytherapy is associated with inferior effectiveness and increased toxicity compared with whole breast irradiation in older patients. Presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. December 6-10, 2011. Abstract S2-1.?

Posted December 13, 2011?


View the original article here